167 related articles for article (PubMed ID: 21757154)
21. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.
Jenny NS; Solomon C; Cushman M; Tracy RP; Nelson JJ; Psaty BM; Furberg CD
Atherosclerosis; 2010 Apr; 209(2):528-32. PubMed ID: 19804884
[TBL] [Abstract][Full Text] [Related]
23. Racial variation in lipoprotein-associated phospholipase A₂ in older adults.
Lee KK; Fortmann SP; Varady A; Fair JM; Go AS; Quertermous T; Hlatky MA; Iribarren C
BMC Cardiovasc Disord; 2011 Jun; 11():38. PubMed ID: 21714927
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.
Nelson TL; Biggs ML; Kizer JR; Cushman M; Hokanson JE; Furberg CD; Mukamal KJ
J Clin Endocrinol Metab; 2012 May; 97(5):1695-701. PubMed ID: 22399516
[TBL] [Abstract][Full Text] [Related]
25. Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes.
Constantinides A; van Pelt LJ; van Leeuwen JJ; de Vries R; Tio RA; van der Horst IC; Sluiter WJ; Dullaart RP
Eur J Clin Invest; 2011 Aug; 41(8):820-7. PubMed ID: 21281278
[TBL] [Abstract][Full Text] [Related]
26. Lp-PLA2: A new target for statin therapy.
Braun LT; Davidson MH
Curr Atheroscler Rep; 2010 Jan; 12(1):29-33. PubMed ID: 20425268
[TBL] [Abstract][Full Text] [Related]
27. Effects of Extended-Release Niacin on Quartile Lp-PLA
Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
[TBL] [Abstract][Full Text] [Related]
28. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
Davidson MH; Bays HE; Stein E; Maki KC; Shalwitz RA; Doyle R;
Clin Cardiol; 2006 Jun; 29(6):268-73. PubMed ID: 16796078
[TBL] [Abstract][Full Text] [Related]
29. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy.
McPherson R; Agnani G; Lau P; Fruchart JC; Edgar AD; Marcel YL
Arterioscler Thromb Vasc Biol; 1996 Nov; 16(11):1340-6. PubMed ID: 8911272
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
; Thompson A; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Ballantyne C; Cannon CP; Criqui M; Cushman M; Hofman A; Packard C; Thompson SG; Collins R; Danesh J
Lancet; 2010 May; 375(9725):1536-44. PubMed ID: 20435228
[TBL] [Abstract][Full Text] [Related]
31. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients.
Wang AY; Lam CW; Wang M; Woo J; Chan IH; Lui SF; Sanderson JE; Li PK
Am J Kidney Dis; 2005 Apr; 45(4):715-29. PubMed ID: 15806475
[TBL] [Abstract][Full Text] [Related]
32. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.
Persson M; Berglund G; Nelson JJ; Hedblad B
Atherosclerosis; 2008 Sep; 200(1):191-8. PubMed ID: 18201705
[TBL] [Abstract][Full Text] [Related]
33. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Mangili A; Ahmad R; Wolfert RL; Kuvin J; Polak JF; Karas RH; Wanke CA
Clin Infect Dis; 2014 Mar; 58(6):893-900. PubMed ID: 24336757
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
Suzuki T; Solomon C; Jenny NS; Tracy R; Nelson JJ; Psaty BM; Furberg C; Cushman M
Circ Heart Fail; 2009 Sep; 2(5):429-36. PubMed ID: 19808373
[TBL] [Abstract][Full Text] [Related]
36. Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study.
Tselepis AD; Panagiotakos DB; Pitsavos C; Tellis CC; Chrysohoou C; Stefanadis C
Atherosclerosis; 2009 Sep; 206(1):303-8. PubMed ID: 19394616
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.
Tselepis AD; Hahalis G; Tellis CC; Papavasiliou EC; Mylona PT; Kourakli A; Alexopoulos DC
J Lipid Res; 2010 Nov; 51(11):3331-41. PubMed ID: 20625038
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Ross Eckard A; Longenecker CT; Jiang Y; Debanne SM; Labbato D; Storer N; McComsey GA
HIV Med; 2014 Oct; 15(9):537-46. PubMed ID: 24650269
[TBL] [Abstract][Full Text] [Related]
39. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
[TBL] [Abstract][Full Text] [Related]
40. Effects of A379V variant of the Lp-PLA 2 gene on Lp-PLA 2 activity and markers of oxidative stress and endothelial function in Koreans.
Chae JS; Kwak JH; Kim M; Shin KH; Lee SH; Jeong TS; Lee JH
J Thromb Thrombolysis; 2014 Nov; 38(4):477-84. PubMed ID: 24682749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
